Denali Therapeutics (DNLI) Invested Capital: 2017-2025
Historic Invested Capital for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $931.8 million.
- Denali Therapeutics' Invested Capital fell 29.63% to $931.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $931.8 million, marking a year-over-year decrease of 29.63%. This contributed to the annual value of $1.2 billion for FY2024, which is 20.18% up from last year.
- Denali Therapeutics' Invested Capital amounted to $931.8 million in Q3 2025, which was down 9.89% from $1.0 billion recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Invested Capital peaked at $1.5 billion during Q1 2024, and registered a low of $812.7 million during Q3 2022.
- Moreover, its 3-year median value for Invested Capital was $1.1 billion (2025), whereas its average is $1.2 billion.
- Its Invested Capital has fluctuated over the past 5 years, first soared by 113.62% in 2021, then fell by 29.63% in 2025.
- Quarterly analysis of 5 years shows Denali Therapeutics' Invested Capital stood at $962.3 million in 2021, then climbed by 8.78% to $1.0 billion in 2022, then fell by 1.52% to $1.0 billion in 2023, then rose by 20.18% to $1.2 billion in 2024, then declined by 29.63% to $931.8 million in 2025.
- Its Invested Capital was $931.8 million in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.1 billion in Q1 2025.